FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Core Viewpoint - The FDA has extended the conditional approval for Canalevia-CA1, a treatment for chemotherapy-induced diarrhea in dogs, through December 2026, with a confirmatory effectiveness trial expected to conclude in February 2026 [1] Group 1 - The FDA's renewal of conditional approval allows continued availability of Canalevia-CA1, which is a prescription drug for treating CID in dogs [1] - Currently, 51 dogs have been enrolled in the effectiveness trial, with approximately 49 more expected to participate [1] - Canalevia-CA1 is distributed by multiple leading veterinary distributors in the U.S., including Chewy [1]